BLA 103950 · Biovitrum Ab
Kineret
Anakinra · Subcutaneous · Interleukin-1 Receptor Antagonist
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Nov 14, 2001
Approved uses
6
Original approval plus efficacy supplements
Registered trials
188
40 Phase 3, 18 recruiting
FAERS reports
16,900
11,721 serious, 1,576 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 3, 2026.
KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) ( 1.1 ) Cryopyrin-Associated Periodic Syndromes (CAPS) Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) ( 1.2 ) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) ( 1.3 ) 1.1 Active Rheumatoid Arthritis KINERET is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs). KINERET can be used alone or in combination with DMARDs other than Tumor Necrosis Factor (TNF) blocking agents [see Warnings and Precautions ( 5.2 )]. 1.2 Cryopyrin-Associated Periodic Syndromes (CAPS) KINERET is indicated for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). 1.3 Deficiency of Interleukin-1 Receptor Antagonist (DIRA) KINERET is indicated for the treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Mechanism: KINERET blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. IL-1 has a broad range of activities including cartilage degradation by its induction of the rapid loss of proteoglycans, as well as stimulation of bone resorption. The levels of the naturally occurring IL-1Ra in synovium and...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2020 Supplement 5189 · Efficacy · priority review OrphanLabelLetter
- Dec 21, 2012 Supplement 5136 · Efficacy · priority review LetterLabel
- Dec 15, 2006 Supplement 5064 · Efficacy
- Feb 22, 2006 Supplement 5061 · Efficacy
- Aug 22, 2003 Supplement 5019 · Efficacy Letter
- Nov 14, 2001 Original approval · Type 1 - New Molecular Entity NovelOrphanPatient Package InsertLabelReview
3 products under this application
- KINERET · ANAKINRA 25MIU/VIAL · VIAL, SUBCUTANEOUS · Prescription
- KINERET · ANAKINRA 10MIU/VIAL · VIAL, SUBCUTANEOUS · Prescription
- KINERET · ANAKINRA 18MIU/VIAL · VIAL, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Anakinra" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06381661 · 2,000 participants (planned) · Start Jul 9, 2026 · Primary completion Aug 9, 2028
Drug: Tocilizumab; Baricitinib and 13 more · For: Sepsis
Sites: Dijon, France; Étampes, France; Garches, France · 19 sites in all
Hellenic Institute for the Study of SepsisAcademic, hospital or other
NCT04357366 · 1,000 participants · Start Apr 15, 2020 · Primary completion Jan 29, 2022
Drug: Anakinra · For: COVID-19; Virus Diseases; Corona Virus Infection and 1 more
Sites: Marousi, Greece; Alexandroupoli, Greece; Athens, Greece · 28 sites in all
- SC IL-1Ra in SAH - Phase III Trial (SCIL)Pivotal-lookingStatus unknown
University of ManchesterAcademic, hospital or other
NCT03249207 · 612 participants · Start Oct 11, 2018 · Primary completion Apr 2024
Drug: IL-1Ra; IL-1Ra Placebo · For: Subarachnoid Hemorrhage
Sites: Plymouth, United Kingdom; Sheffield, United Kingdom; Cardiff, United Kingdom · 17 sites in all
- suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19Pivotal-lookingCompleted
Hellenic Institute for the Study of SepsisAcademic, hospital or other
NCT04680949 · 606 participants · Start Dec 23, 2020 · Primary completion Mar 31, 2021
Drug: Anakinra; Placebo · For: Covid19
Sites: Alexandroupoli, Greece; Athens, Greece; Corfu, Greece · 40 sites in all
- Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODSPivotal-lookingRecruiting
Nationwide Children's HospitalAcademic, hospital or other
NCT05267821 · 500 participants (planned) · Start Jun 14, 2022 · Primary completion May 15, 2028
Drug: Anakinra; Placebo · For: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 32 sites in all
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"Pivotal-lookingNot yet recruiting
Yale UniversityAcademic, hospital or other
NCT07281027 · 438 participants (planned) · Start Dec 1, 2026 · Primary completion Mar 31, 2030
Drug: Anakinra; Tocilizumab · For: New Onset Refractory Status Epilepticus; New-Onset Refractory Status Epilepticus; Febrile Infection-Related Epilepsy Syndrome (FIRES)
Sites: Phoenix, Arizona; Aurora, Colorado; New Haven, Connecticut · 33 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use5,297
- drug ineffective4,355
- condition aggravated1,743
- pain1,603
- rheumatoid arthritis1,556
- arthralgia1,207
- joint swelling1,192
- pyrexia1,189
- drug intolerance1,168
- injection site pain1,047
- rash996
- nausea961
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 118 |
| 2005 | 58 |
| 2006 | 111 |
| 2007 | 253 |
| 2008 | 276 |
| 2009 | 88 |
| 2010 | 75 |
| 2011 | 80 |
| 2012 | 109 |
| 2013 | 117 |
| 2014 | 107 |
| 2015 | 186 |
| 2016 | 563 |
| 2017 | 864 |
| 2018 | 1,078 |
| 2019 | 1,586 |
| 2020 | 3,066 |
| 2021 | 1,624 |
| 2022 | 1,845 |
| 2023 | 1,210 |
| 2024 | 1,289 |
| 2025 | 1,182 |
| 2026 | 1,015 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kineret (Anakinra)
2024 spending
$32.1M
Beneficiaries
921
5,321 claims
Per beneficiary
$34,895
$291.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $19,061,039 |
| 2021 | $21,497,994 |
| 2022 | $23,620,004 |
| 2023 | $28,024,001 |
| 2024 | $32,138,063 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.
Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, et al. · JAMA 2026 · Clinical Trial, Phase II, Multicenter Study
- Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.
Leventogiannis K, Kyriazopoulou E, Antonakos N, et al. · Cell Rep Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Treatment of relapsing polychondritis: a systematic review.
Petitdemange A, Sztejkowski C, Damian L, et al. · Clin Exp Rheumatol 2022 · Systematic Review
- Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review.
Charlesworth JEG, Kavirayani A · Eur J Haematol 2023 · Systematic Review
- Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD, Yalamanoglu A, Boyman O · Front Immunol 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.
Bindoli S, De Matteis A, Mitrovic S, et al. · Ann Rheum Dis 2024 · Systematic Review
Sponsor: Biovitrum Ab
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.